Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
NCT ID: NCT00051688
Last Updated: 2006-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
INTERVENTIONAL
2003-06-30
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tezacitabine
oxaliplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have at least one measurable tumor.
* Patients may not have received prior treatment with oxaliplatin.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiron Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACRC/Arizona Clinical Research Center
Tucson, Arizona, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States
Cancer Institute Medical Group
Santa Monica, California, United States
Georgetown University Medical Center, Lombardi Cancer Center
Washington D.C., District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEZ101
Identifier Type: -
Identifier Source: org_study_id